Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04530630 · ClinicalTrials.gov registry record · Phase 4
Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/F/TAF) After Renal Transplant
A Phase 4 study, sponsored by Weill Medical College of Cornell University.
- Completed
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
NCT04530630 is a Phase 4 study that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 20 participants.
The verdict
NCT04530630, a Phase 4 study, has completed, sponsored by Weill Medical College of Cornell University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
Study Summary
This is an open-label study, where participants will be switched from their current HIV medication to the study drug, BIC/F/TAF. Open-label means both the investigator and the participant will know what drug will be given. Participants will be followed for 48 weeks in order to monitor the efficacy, safety and tolerability of BIC/F/TAF. The investigator hypothesizes that BIC/F/TAF will be an important addition to the management of HIV-positive post renal transplant patients, especially since it is a one pill daily dosing regimen, thereby decreasing the pill burden in this population.
Interventions
- DRUG BIC/F/TAF 50Mg-200Mg-25Mg Tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2020-11-09 |
| Est. Completion | 2024-08-28 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04530630
The ClinicalTrials.gov registry entry for NCT04530630 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BIC/F/TAF 50Mg-200Mg-25Mg Tablet is the first listed.
NCT04530630 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04530630 about?
NCT04530630 is a clinical study titled "Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/F/TAF) After Renal Transplant". This is an open-label study, where participants will be switched from their current HIV medication to the study drug, BIC/F/TAF. Open-label means both the investigator and the participant will know what drug will be given. Participants will be followed for 48 weeks in order to monitor the efficacy, ...
What is the current status of trial NCT04530630?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2020-11-09. Estimated completion is 2024-08-28.
What interventions are being tested in trial NCT04530630?
The interventions under investigation include: BIC/F/TAF 50Mg-200Mg-25Mg Tablet (DRUG).
Who is sponsoring clinical trial NCT04530630?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.